IP Library › Granted Patent US 12,257,326
Granted Patent B2
US 12,257,326 · App. 17/018,314 · Granted Mar 25, 2025

TCO conjugates and methods for delivery of therapeutic agents

Inventors: Jose Manuel Mejia Oneto (Oakland, CA); Maksim Royzen (Albany, NY)
Assignees: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A61K51/065A61K31/43A61K31/7076A61K38/12A61K38/14A61K47/54A61K47/542A61K47/545A61K47/61A61K47/665A61K47/6903A61K49/0041A61K49/0043A61K49/0052A61K49/0054A61K49/0073A61K51/0482A61K51/0495A61K51/1213C07D257/08C07D311/82C07D499/74C07H7/02C07H15/24C07H19/167C07H19/213
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,257,326
App. No.
17/018,314
Granted
Mar 25, 2025
Kind
B2
Abstract

The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.

Claims (33)

1. A solid support composition comprising:

a biocompatible solid support;

at least one binding agent; and

a linker comprising from about 1 to about 10 linking atoms, covalently linking each binding agent to the biocompatible solid support,

wherein the binding agent and the linker together have the structure selected from the group consisting of:

2. The composition of claim 1 , wherein the solid support comprises a hydrogel.

3. The composition of claim 1 , wherein the solid support comprises alginate.

4. The composition of claim 1 , wherein the solid support comprises agarose.

5. The composition of claim 1 , wherein the binding agent and the linker together have the structure selected from the group consisting of:

6. The composition of claim 1 , wherein the composition has the structure selected from the group consisting of:

7. A method for selectively delivering an effective amount of a therapeutic or diagnostic agent to a first location of a targeted organ or tissue in a patient, comprising the steps of:

(a) implanting in the patient at the first location of the targeted organ or tissue a solid support composition comprising a biocompatible solid support, a first binding agent, and a linker comprising from about 1 to about 10 linking atoms, covalently linking the binding agent to the biocompatible solid support; and

(b) administering to the patient a bioactive composition comprising a therapeutic or diagnostic agent, a second binding agent, and a linker comprising from about 1 to about 10 linking atoms, covalently linking the binding agent to the therapeutic or diagnostic agent, wherein the first and second binding agents bind to one another upon contact,

wherein the therapeutic or diagnostic agent is released,

thereby selectively delivering the effective amount of the therapeutic or diagnostic agent to the first location of the targeted organ or tissue in the patient,

wherein the first and second binding agents are each selected from the group consisting of trans-cyclooctene and tetrazine such that one of the first and second binding agents is trans-cyclooctene and one of the first and second binding agents is tetrazine.

8. The method of claim 7 , wherein the first binding agent is trans-cyclooctene and the second binding agent is tetrazine.

9. The method of claim 7 , wherein the second binding agent is 1,2,4,5-tetrazine.

10. The method of claim 7 , wherein the solid support composition is:

11. The method of claim 7 , wherein

the solid support composition is:

 and

the bioactive composition is selected from the group consisting of:

wherein R is selected from the group consisting of the therapeutic agent and the diagnostic agent.

12. The method of claim 7 , wherein the targeted organ or tissue is bone.

13. The method of claim 7 , wherein the concentration of the therapeutic or diagnostic agent at the first location of the targeted organ or tissue is greater than the concentration elsewhere in the patient.

14. The method of claim 7 , wherein the therapeutic agent is vancomycin.

15. The composition of claim 1 , wherein the solid support is selected from a group consisting of a polysaccharide hydrogel, alginate, agarose, cellulose, hyaluronic acid, chitosan, chitin, chondroitin sulfate, heparin, polymer matrix, a metal, a ceramic, and a plastic, each of which may be optionally modified.

16. The composition of claim 15 , wherein the plastic is selected from the group consisting of polyphosphazenes, polyanhydrides, polyacetals, poly(ortho esters), polyphosphoesters, polycaprolactones, polyurethanes, polylactides, polycarbonates, polyamides, polyethers, and co-polymers thereof.

17. The composition of claim 1 , wherein the solid support comprises a carboxymethyl modification of hydroxyl or amino groups.

18. The composition of claim 1 , wherein the solid support is modified by esterification of carboxylic acids, conversion of alcohols to ethers or esters, or conversion of acids or amines to amides.

19. The composition of claim 1 , wherein the solid support comprises proteins and other poly(amino acids).

20. The composition of claim 19 , wherein the proteins and other poly(amino acids) are selected from the group consisting of collagen, gelatin, elastin and elastin-like polypeptides, albumin, fibrin, poly(gamma-glutamic acid), poly(L-lysine), poly(L-glutamic acid), and poly(aspartic acid).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2020
From: MEJIA ONETO, JOSE MANUEL
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 054428/0462 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2020
From: ROYZEN, MAKSIM
To: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Reel/Frame 054428/0546 →
Continuity (8)
Continuation 16156418 · Oct 10, 2018
Continuation 15382402 · Dec 16, 2016
Continuation 15265158 · Sep 14, 2016
Continuation PCTUS2015020718 · Mar 16, 2015
Provisional Application 62083022 · Nov 21, 2014
Provisional Application 62013994 · Jun 18, 2014
Provisional Application 61953294 · Mar 14, 2014
Related Publication 20210060188A1 · Mar 4, 2021
References Cited (127)
US 5770229A · Tanihara et al. · 1998 [cited by applicant]
US 8552183B2 · Wiessler et al. · 2013 [cited by applicant]
US 9421274B2 · Robillard et al. · 2016 [cited by applicant]
US 9427482B2 · Rossin et al. · 2016 [cited by applicant]
US 9463256B2 · Lub et al. · 2016 [cited by applicant]
US 10130711B2 · Mejia Oneto et al. · 2018 [cited by applicant]
US 10130723B2 · Mejia Oneto et al. · 2018 [cited by applicant]
US 10342882B2 · Mejia Oneto et al. · 2019 [cited by applicant]
US 10806807B2 · Mejia Oneto et al. · 2020 [cited by applicant]
US 10953098B2 · Mejia Oneto et al. · 2021 [cited by applicant]
US 20050014197A1 · Agnew et al. · 2005 [cited by applicant]
US 20090023916A1 · Fox et al. · 2009 [cited by applicant]
US 20110223257A1 · Zhao et al. · 2011 [cited by applicant]
US 20110268654A1 · Hilderbrand et al. · 2011 [cited by applicant]
US 20120034161A1 · Robillard et al. · 2012 [cited by applicant]
US 20120076727A1 · McBride et al. · 2012 [cited by applicant]
US 20130281644A1 · Kiessling et al. · 2013 [cited by applicant]
US 20130302246A1 · Hilderbrand et al. · 2013 [cited by applicant]
US 20140199331A1 · Robillard et al. · 2014 [cited by applicant]
US 20150328164A1 · Joshi · 2015 [cited by applicant]
US 20150328314A1 · Friedman et al. · 2015 [cited by applicant]
US 20160114046A1 · Brudno et al. · 2016 [cited by applicant]
US 20160120987A1 · Mejia Oneto et al. · 2016 [cited by applicant]
US 20170087258A1 · Oneto et al. · 2017 [cited by applicant]
US 20170095580A1 · Mejia Oneto et al. · 2017 [cited by applicant]
EP 1867638 · 2007 [cited by applicant]
EP 2719400 · 2014 [cited by applicant]
JP 2006507232A · 2006 [cited by applicant]
JP 2009513696A · 2009 [cited by applicant]
JP 2010036032A · 2010 [cited by applicant]
WO WO03000708 · 2003 [cited by applicant]
WO WO2003084571 · 2003 [cited by applicant]
WO WO2004009082 · 2004 [cited by applicant]
WO WO2006003014 · 2006 [cited by applicant]
WO WO2006013337 · 2006 [cited by applicant]
WO WO2010019233 · 2010 [cited by applicant]
WO WO2010051530 · 2010 [cited by applicant]
WO WO2010096654 · 2010 [cited by applicant]
WO WO2011012715 · 2011 [cited by applicant]
WO WO2011127149 · 2011 [cited by applicant]
WO WO2011140392 · 2011 [cited by applicant]
WO WO2012012612 · 2012 [cited by applicant]
WO WO2012049624 · 2012 [cited by applicant]
WO WO2012074840 · 2012 [cited by applicant]
WO WO2012085789 · 2012 [cited by applicant]
WO WO2012156918 · 2012 [cited by applicant]
WO WO2012156919 · 2012 [cited by applicant]
WO WO2012156920 · 2012 [cited by applicant]
WO WO2012153254 · 2012 [cited by applicant]
WO WO2012165462 · 2012 [cited by applicant]
WO WO2012168512 · 2012 [cited by applicant]
WO WO2013187954 · 2013 [cited by applicant]
WO WO2014065860 · 2014 [cited by applicant]
WO WO2014081299 · 2014 [cited by applicant]
WO WO2014081300 · 2014 [cited by applicant]
WO WO2014081301 · 2014 [cited by applicant]
WO WO2014081303 · 2014 [cited by applicant]
WO WO2014117001 · 2014 [cited by applicant]
WO WO2014138186 · 2014 [cited by applicant]
WO WO2014200767 · 2014 [cited by applicant]
WO WO2014205126 · 2014 [cited by applicant]
WO WO2015139025 · 2015 [cited by applicant]
WO WO2015154082 · 2015 [cited by applicant]
Selvaraj et al., “Tetrazine-tans-cyclooctene ligation for the rapid construction of integrin α [cited by applicant]
Habnouni et al., “Mild methodology for the Versatile Chemical Modification of Polyactide Surfaces: Original Combination of Anionic and Click Chemistry for Biomedical Applications,” Advanced Functional Materials, 21, pp.… [cited by applicant]
Saito et al., “Prolonged ectopic calcification induced by BMP-2-derived synthetic peptide,” Journal of Biomedical Materials Research, 70A, pp. 115-121 (2004). [cited by applicant]
Extended European Search Report corresponding to European Patent Application 16845300.0 mailed Apr. 17, 2019, 13 pages. [cited by applicant]
Mejia Oneto et al., “In vivo Bioorthogonal Chemistry Enables Local Hydrogel and Systemic Pro-Drug To Treat Soft Tissue Sarcoma,” ACS Central Science, 2(7), pp. 476-482 (2016). [cited by applicant]
Guo et al., “Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy,” International Journal of Pharmaceutics, Elsevier, NL, 451(1) pp. 1-11 (20… [cited by applicant]
Drury et al., “Hydrogels for tissue engineering: scaffold design variables and applications,” Biomaterials, 24(24), pp. 4337-4351 (2003). [cited by applicant]
Al-Dubai et al., “Biocompatible medical implant materials with binding sites for a biodegradable drug-delivery system,” Nanotechnology, Science and Applications, 2011(4), pp. 87-94 (2011). [cited by applicant]
Alge et al. “Synthetically tractable click hydrogels for three-dimensional cell culture formed using tetrazine-norbornene chemistry,” Biomacromolecules, 14(4), pp. 949-953 (Apr. 8, 2013, e-published Mar. 8, 2013). [cited by applicant]
Altin et al., “Fabrication of ”Clickable“ Hydrogels via Dendron-Polymer Conjugates,” Macromolecules, 43(8), pp. 3801-3808 (2010). [cited by applicant]
Antoci Jr. et al., “The inhibition of [cited by applicant]
Blackman et al., “Tetrazine Ligation: Fast Bioconjugation Based on Inverse-Electron-Demand Diels-Alder Reactivity,” J. Am. Chem. Soc., 130, pp. 13518-13519 (2008). [cited by applicant]
Brudno et al., “In Vivo Targeting through Click Chemistry,” Chem. Med. Chem., 10, pp. 617-620 (2015). [cited by applicant]
Brudno et al., “On-demand drug delivery from local depots,” J. Control. Release, 10 pages (2015). [cited by applicant]
Budin et al., “Bioorthogonal Probes for Polo-like Kinase 1 Imaging and Quantification”, Angew. Chem. Int. Ed., 50(40), pp. 9378-9381 (2011). [cited by applicant]
Burdick et al., Acellular Biomaterials: An Evolving Alternative to Cell-Based Therapies, Science Translation Medicine, 5(176), 4 pages (2013). [cited by applicant]
Chung et al., “Ubiquitous Detection of Gram-Positive Bacteria with Bioorthogonal Magnetofluorescent Nanoparticles,” ASC Nano, 5(11), pp. 8834-8841 (2011). [cited by applicant]
Cok et al., “Synthesis of Model Network Hydrogels via Tetrazine-Olefin Inverse Electron Demand Diels-Alder Cycloaddition,” Macromol. Symp., 329, pp. 108-112 (2013). [cited by applicant]
Coviello et al., “Polysaccharide hydrogels for modified release formulations,” Journal of Controlled Release, 119, pp. 5-24 (2007). [cited by applicant]
Deforest et al., “Sequential click reactions for synthesizing and patterning three-dimensional cell microenvironments,” Nature Materials: Letters, 8, pp. 659-664 (2009). [cited by applicant]
Desai et al., “Versatile click alginate hydrogels crosslinked via tetrazineenorbomene chemistry,” Biomaterials, 50, pp. 30-37 (2015). [cited by applicant]
Devaraj et al., “Fast and Sensitive Pretargeted Labeling of Cancer Cells through a Tetrazine/trans-Cyclooctene Cycloaddition,” Angew. Chem. Int. Ed., 48, pp. 7013-7016 (2009). [cited by applicant]
Devaraj et al., “Biomedical Applications of Tetrazine Cycloadditions”, Accounts of Chemical Research, 44(9), pp. 816-827 (2011). [cited by applicant]
Eckhouse et al., “Local Hydrogel Release of Recombinant TIMP-3 Attenuates Adverse Left Ventricular Remodeling After Experimental Myocardial Infarction,” Science Translation Medicine, 6(223), 10 pages (2014). [cited by applicant]
Eschenhagen et al., “Physiological aspects of cardiac tissue engineering,” Am. J. Physiol. Heart Circ. Physiol., 30, pp. H133-H143 (2012). [cited by applicant]
Extended European Search Report mailed Aug. 10, 2017 for EP Application 15761367.0, 13 pages. [cited by applicant]
Extended European Search Report mailed Dec. 2, 2016 for European Application 14813532.0, 10 pages. [cited by applicant]
Godoy et al. “Enhanced activity of an immobilized lipase promoted by site-directed chemical modification with polymers,” Process Biochemistry 45(4), pp. 534-541 (2010). [cited by applicant]
Hashida et al., “Timed-Release of Mitomycin C from Its Agarose Bead Conjugate,” Chem. Pharm. Bull., 25, pp. 2456-2458 (1977). [cited by applicant]
Hofmann et al., “Targeted delivery of vancomycin to Staphylococcus epidermidis biofilms using a fibrinogen-derived peptide,” J. Biomed Mater. Res. A, 100(9), pp. 2517-2525 (Sep. 2012, e-published May 24, 2012). [cited by applicant]
International Search Report for International Application No. PCT/US2014/043020 mailed Oct. 6, 2014, 2 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2015/020718 mailed Jun. 10, 2015, 8 pages. [cited by applicant]
Kharkar et al., “Designing degradable hydrogels for orthogonal control of cell microenvironments,” Chem. Soc. Rev., 42(17), pp. 7335-7372 (2013). [cited by applicant]
Kojima et al. “Antitumor activity of timed-release derivative of mitomycin C, agarose bead conjugate,” Chem. Pharm. Bull. 26(6), pp. 1818-1824 (Jun. 1978). [cited by applicant]
Koo et al., “Bioorthogonal Copper-Free Click Chemistry In Vivo for Tumor-Targeted Delivery of Nanoparticles,” Angew. Chem. Int. Ed., 51, pp. 11836-11840 (2012). [cited by applicant]
Korpela et al. “A simple method to introduce aldehydic function to agarose,” Anal. Biochem., 71(1), pp. 322-323 (Mar. 1976). [cited by applicant]
Koshy et al., “Click-Crosslinked Injectable Gelatin Hydrogels,” Advanced Healthcare Materials, 7 pages (2016). [cited by applicant]
Landa et al., “Effect of Injectable Alginate Implant on Cardiac Remodeling and Function After Recent and Old Infarcts n Rat,” Circulation, 17, pp. 1388-1396 (2008). [cited by applicant]
Li et al., “Monodispersed PEG-DOT A Conjugated Anti-Tag-72 Diabody Has Low Kidney Uptake and High Tumor to Blood Ratios Resulting in Improved 64 Cu PET Imaging,” J. Nucl. Med., 51(7), pp. 1139-1146 (2011). [cited by applicant]
Li et al., “Diels-Alder reaction-triggered bioorthogonal protein decaging in living cells,” Natural Chemical Biology, Advanced Online Publication, Nov. 2, 2014 (5 pages). [cited by applicant]
Matikonda et al., “Bioorthogonal prodrug activation driven by a strain-promoted 1,3-dipolar cycloaddition,” Chem. Sci., 6, pp. 1212-1218 (2015). [cited by applicant]
Miejia Oneto et al., “Implantable biomaterial based on click chemistry for targeting small molecules,” Acta Biomaterials, 10, pp. 5099-5105 (2014). [cited by applicant]
Neves et al., “Imaging Cell Surface Glycosylation in Vivo Using “Double Click” Chemistry,” Bioconjugate Chem., 24, pp. 934-941 (2013). [cited by applicant]
Niska et al., “Vancomycin-rifampin combination therapy has enhanced efficacy against an experimental [cited by applicant]
Patterson et al., “Finding the Right (Bioorthogonal) Chemistry,” ACS Chem. Biol., 9, pp. 592-605 (2014). [cited by applicant]
Pretze et al., “Recent Trends in Bioorthogonal Click-Radiolabeling Reactions Using Fluorine-18”, Molecules, 18, Jul. 22, 2013, pp. 8618-8665; doi:10.3390/molecules18078618. [cited by applicant]
Reiner et al. “The inverse electron demand Diets-Alder click reaction in radiochemistry,” J. Labelled Comp. Radiopharm., 57(4), pp. 285-290 (2014). [cited by applicant]
Rossin et al., “In Vivo Chemistry for Pretargeted Tumor Imagining in Live Mice,” Angew. Chem. Int. Ed., 49, pp. 3375-3378 (2010). [cited by applicant]
Rossin et al., “Supporting Information for In Vivo Chemistry for Pretargeted Tumor Imagining in Live Mice,” Sections S1-S6, pp. S2-S21 (2010). [cited by applicant]
Royzen et al., “A Photochemical Synthesis of Functionalized trans-Cyclooctenes Driven by Metal Composition,” J. Am. Chem. Soc., 130, pp. 3760-3761 (2008). [cited by applicant]
Seif-Naraghi et al., “Safety and Efficacy of an Injectable Extracellular Matrix Hydrogel for Treating Myocardial Infarction,” Science Translation Medicine, 5(173), 10 pages (2013). [cited by applicant]
Selvaraj et al., “trans-Cyclooctene—a stable, voracious dienophile for bioorthogonal labeling,” Curr. Opin. Chem. Biol., 17(5), pp. 753-760 (Oct. 2013). [cited by applicant]
Shelke et al., “Polysaccharide biomaterials for drug delivery and regenerative engineering,” Polym. Adv. Technol., 25, pp. 448-460 (2014). [cited by applicant]
Sluyterman et al. “Chromatofocusing,” Journal of Chromatography 206(3), pp. 441-447 (1981). [cited by applicant]
Thalhammer et al., Reaktivitat Einfacher Offenkettiger Und Cyclischer Dienophile Bei Diels-Alder-Reaktionen Mit Inversem Elektronenbedarf, Tetrahedron Letters, 31(47), pp. 3851-6854 (1991). [cited by applicant]
Thomas et al., “Polyvalent Dendrimer-Methotrexate as a Folate Receptor-Targeted Cancer Therapeutic,” Molecular Pharmaceutics, 9, pp. 2669-2676 (2012). [cited by applicant]
Tritton et al., “The anticancer agent adriamycin can be actively cytotoxic without entering cells,” Science, 217(4556), 248-250 ((1982). [cited by applicant]
Versteegen et al., “Click to Release: Instantaneous Doxorubicin Elimination upon Tetrazine Ligation,” Angew. Chem. Int. Ed., 52, pp. 14112-14116 (2013). [cited by applicant]
Zeglis et al., “A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels-Alder Click Chemistry,” J. Nucl. Med., 54(8), pp. 1389-1396 (2013). [cited by applicant]
Zeglis et al. “Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels-Alder Click Chemistry,” Bioconjugate Chemistry, 22, pp. 2048-2059… [cited by applicant]
Zeglis et al., “Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide; Synthesis,” Chemistry Open Communications, 3, pp. 48-53 (2014). [cited by applicant]
Zhang et al., “An ionically crosslinked hydrogel containing vancomycin coating on a porous scaffold for drug delivery and cell culture,” International Journal of Pharmaceuticals, 353(1-2), pp. 74-87 (2007). [cited by applicant]
Zhang et al., “Preparation of Small-Molecule Microarrays by trans-Cylcooctene Tetrazine Ligation and Their Application in the High-Throughput Screening of Protein-Protein Interaction Inhibitors of Bromodomains,” Angew. … [cited by applicant]
Devaraj et al., “Reactive polymer enables efficient in vivo bioorthogonal chemistry,” PNAS, 109(13), pp. 4762-4767 (2012). [cited by applicant]